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MaBACKGROUND Human induced pluripotent stem cells (iPSCs) play an important role in disease modeling and drug
testing. However, the current methods are time-consuming and lack an isogenic control.
OBJECTIVES This study sought to establish an efﬁcient technology to generate human PSC-based disease models
with isogenic control.
METHODS The ion channel genes KCNQ1 and KCNH2 with dominant negative mutations causing long QT syndrome
types 1 and 2, respectively, were stably integrated into a safe harbor AAVS1 locus using zinc ﬁnger nuclease technology.
RESULTS Patch-clamp recording revealed that theedited iPSC-derived cardiomyocytes (iPSC-CMs) displayed characteristic
long QT syndrome phenotype and signiﬁcant prolongation of the action potential duration compared with the unedited
control cells. Finally, addition of nifedipine (L-type calcium channel blocker) or pinacidil (KATP-channel opener) shortened
the action potential duration of iPSC-CMs, conﬁrming the validity of isogenic iPSC lines for drug testing in the future.
CONCLUSIONS Our study demonstrates that iPSC-CM-based disease models can be rapidly generated by over-
expression of dominant negative gene mutants. (J Am Coll Cardiol 2014;64:451–9) © 2014 by the American College of
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452are considered to be an inexhaustible, scal-
able, and biologically matched material for
cardiovascular studies.
For human disease modeling, the ﬁrst step is
to obtain iPSCs with disease-causing genetic
mutations and subsequently differentiate them
into the disease-relevant cell types. Disease-
speciﬁc iPSCs can be obtained through the con-
version of somatic cells isolated from patients
with genetic mutations. Through the use of this
approach, several groups have recently modeled
familial dilated cardiomyopathy (5), familial hy-
pertrophic cardiomyopathy (4), Timothy syn-drome (6), LEOPARD (lentigines, electrocardiogram
conduction abnormalities, ocular hypertelorism, pul-
monic stenosis, abnormal genitalia, retardation of growth,
and sensorineural deafness) syndrome (7), arrhythmo-
genic right ventricular dysplasia (8,9), and long QT syn-
drome (LQTS) (3,10,11). However, the limitation of this
approach is that obtaining patient samples with the
desired disease-causing mutation is unpredictable, the
subsequent iPSC generation from skin ﬁbroblasts
or peripheral blood mononuclear cells is time-
consuming, and the disease models generated from
various individuals lack an isogenic unaffected control.
Most current iPSC studies use age-matched, unaffected
cells within the same family pedigree as control (4,10,11),
but these are suboptimal because of differences in the ge-
netic background and other confounders.SEE PAGE 460Recent advances in genome editing technology
allow the direct introduction of speciﬁc genetic mu-
tations into the human PSCs to make disease models,
with the unedited cells serving as an isogenic control.
This technology relies on artiﬁcially engineered nu-
cleases to cut and create speciﬁc double-stranded
breaks at predetermined locations in the genome.
The double-stranded breaks can be repaired by the
cell’s endogenous DNA repair system through either
homologous recombination or non-homologous end-
joining to produce desired mutations. Several diseases
have been modeled with the use of this technique by
introducing mutations into the human PSCs (12,13).
Although the genome editing technology is powerful
for disease modeling, the technology remains a chal-
lenge for the non-specialist.
LQTS is an inherited cardiac arrhythmic disease,
predisposing the patient to life-threatening ventric-
ular arrhythmias and sudden cardiac death. Muta-
tions in the potassium channels, KCNQ1 (LQTS1) and
KCNH2 (LQTS2), account for the 2 most common
clinically deﬁnite LQTS (14). Because KCNQ1 andKCNH2 function as tetramers, a substantial number
of KCNQ1 and KCNH2 mutants display dominant-
negative effect because they interact with wild-type
monomer and impair tetramerization (10,11,14). In
this study, we successfully modeled LQTS by over-
expression of dominant negative mutations in hu-
man PSCs, with the use of unedited human PSCs as
isogenic controls. We further showed that the LQTS
models generated by this approach can be used for
drug screening. Our study demonstrates an easy and
efﬁcient strategy to generate human disease models.
METHODS
An extended Methods section is available in the
Online Appendix.
CELL CULTURE AND MAINTENANCE OF HUMAN
PSCs AND PSC-CMs. Human ESCs (WA09, Wicell,
Madison, Wisconsin) and iPSCs were cultured on
Matrigel-coated plates (ESC qualiﬁed, BD Bio-
sciences, San Diego, California) with the use of hESC
mTeSR-1 cell culture medium (StemCell Technolo-
gies, Vancouver, Canada) under conditions of 37C,
95% air, and 5% CO2 in a humidiﬁed incubator, as
previously described (15). Results for subsequent
experiments are based on 1 hESC line (WA09), four
unedited iPSC lines (2 from healthy individuals,
1 from a patient with G269S mutation, 1 from a
patient with A614V mutation), 4 edited iPSC lines
(with mutations R190Q, G269S, and G345E on
KCNQ1, and A614V on KCNH2, respectively), and
2 edited ESC lines (with mutations G269S on
KCNQ1 and A614V on KCNH2, respectively). All
PSC-CMs were maintained in SCT Cardiac Mainte-
nance Media (Stem Cell Theranostics, Menlo Park,
California).
VECTOR CONSTRUCTION. The DNA fragment con-
taining EF1a promoter was polymerase chain reaction
(PCR)-ampliﬁed from the pCDH_EF1_MCS_T2A_copGFP
vector (System Biosciences, Mountain View, Califor-
nia) and digested with restriction enzymes MluI and
NcoI. The fragment was then inserted into the MluI/
NcoI-cut site of the donor plasmid AAV-CAGGS-eGFP
backbone (Addgene, Cambridge, Massachusetts) (16).
The resultant plasmid was designated AAVS1-EF1a.
Human cDNA clones containing KCNQ1 and KCNH2
were obtained from GeneCopoeia (Rockville, Mary-
land). The coding regions were PCR-ampliﬁed and
cloned into the AAVS1-EF1a KpnI/AgeI site for the
KCNQ1 and AﬂII/EcoRV site for the KCNH2. The
mutations G569A (R190Q on KCNQ1), G805A (G269S
on KCNQ1), G1034A (G345E on KCNQ1), and C821T
(A614V on KCNH2) were generated by Mutagenex Inc
(Piscataway, New Jersey).
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453For gene targeting with the use of AAVS1 zinc
ﬁnger nuclease (ZFNs), refer to the Online Appendix.
For patch-clamp electrophysiology, refer to the
Online Appendix.
For imaging of calcium dynamics in genome edited
iPSC-CMs, refer to the OnlineAppendix.
STATISTICAL ANALYSIS. Results are expressed as
mean  SEM. We used the Student t-test for the
comparison between 2 normally distributed groups of
data. One-way or 2-way analysis of variance followedFIGURE 1 Overexpression of the KCNQ1 and KCNH2 Genes With Dom
(A) Schematic representation of the KCNQ1 and KCNH2 proteins, with the
G269S mutation located in the S5; G345E mutation located in the S6 of t
transmembrane domains (S1 to S6) are ﬂanked by amino (NH2)–terminal
(ZFN)-edited induced pluripotent stem cell (iPSC) lines (ziR190Q, ziG269S
unedited iPSCswere stained by use of anti-KCNQ1 antibody; the upper righ
markers that included Oct4, Tra-1–60, Sox2, Tra-1–81, Nanog, and SSEA4
formed embryoid bodies (EBs) in vitro as shown by bright-ﬁeld (BF) (top l
mesoderm marker smooth muscle actin (SMA) (bottom left), and endode
The teratomas contain all 3 germ layers, identiﬁed here as neural elemenby all pairwise multiple comparison procedures,
where appropriate, was used for the comparison of
multiple groups of data. A value of p < 0.05 was
considered signiﬁcant.
RESULTS
ZFN-MEDIATED TARGETED GENE ADDITION INTO
AAVS1 SAFE HARBOR LOCUS IN ESCs AND IPSCs.
To test the hypothesis that the disease models can be
created by overexpression of genes with dominantinant Negative Mutation at the AAVS1 Locus
R190Q mutation located in the cytoplasmic loop between transmembrane segments S2 and S3;
he KCNQ1 protein; and A614V mutation in the pore region of the KCNH2 protein. The 6
and carboxyl (COOH)–terminal regions. (B) Transgene expression in the zinc ﬁnger nuclease
, ziG345E, and ziA614V) and control cell lines was conﬁrmed by immunostaining. The upper left
t unedited iPSCswere stained by use of anti-KCNH2 antibody. (C) ziG269S expressed pluripotency
. Blue stainings (right) are 40-6-diamidino-2-phenylindole (DAPI) staining of nuclei. (D) ziG269S
eft)microscopic appearance and by expression of the neuroectoderm marker Nestin (top right),
rm marker Sox17 (bottom right). (E) ziG269S formed teratomas in vivo in immunodeﬁcient mice.
t ectoderm (left), cartilage mesoderm (middle), and epithelium endoderm (right).
TABLE 1 Efﬁciency of the Gene Addition to the AAVS1 Locus
Cell
Line Donor
PCR-Positive
Clones/Total
Screened Clones
Clones
Screened by
Southern Blot
Targeted þ
Additional
Integrations
Correct
Targeted
Clones
Het. Homo.
iPSC R190Q 22/23 6 2 3 1
iPSC G269S 22/23 6 4 2 0
iPSC G345E 23/23 6 3 1 1
iPSC A614V 22/23 6 4 0 2
H9 G269S 21/23 6 4 2 0
H9 A614V 21/23 6 3 1 2
Het.¼heterozygous; Homo.¼homozygous; iPSC¼ inducedpluripotent stemcell; PCR¼polymerase chain reaction.
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454negative mutations, we chose three mutations on
KCNQ1 (R190Q, G269S, and G345E) (3,11,17) and 1
mutation on KCNH2 (A614V) (10) to model LQTS1 and
LQTS2, respectively (Fig. 1A). To allow a direct com-
parison of different disease models and avoid muta-
genic random integration or epigenetic silencing
through viral insertions, the transgenes were inserted
into a “safe harbor” AAVS1 locus with the use of zinc
ﬁnger nuclease (ZFN) technology (Online Fig. S1A)
(18). These ion gene mutants were subcloned into the
donor vector driven by the EF1a promoter ﬂanked by
short (800 bp) stretches of homology to the ZFN
target site on chr 19 in exon 1 of the PPP1R12C gene
(16). The donor construct and the ZFN expression
vector were introduced into iPSCs by electroporation.
The ZFN-edited iPSC lines with mutations R190Q,
G269S, G345E, and A614V are designated as ziR190Q,
ziG269S, ziG345E, and ziA614V, respectively.
In addition to these four ZFN-edited iPSC lines,
we also introduced G269S-KCNQ1 and A614V-KCNH2
mutants into human ESCs (WA09); these lines are
designated as H9-G269S and H9-A614V, respectively.
After puromycin selection, 23 clones for each
construct were screened by genomic PCR, 95.2%
(197/207) of which carried the transgenic cassette
at the ZFN-speciﬁed location (Online Fig. S1B,
Table 1). Of these PCR-positive clones, 6 clones for
each mutation were further screened by Southern
blotting (Online Fig. S1C, Table 1). The results
revealed that all the clones contained 1 or 2
copies of targeted gene addition, except for 1 from
ziG345E. We next genotyped a panel of putative ZFN
off-target sites for each mutation (Online Fig. S2),
and data demonstrate all to be wild-type, in agree-
ment with previous studies on the robust speciﬁcity
of this ZFN set (16,18). After extensive genetic char-
acterization, immunostaining conﬁrmed the trans-
gene expression (Fig. 1B, Online Fig. S3).
GENOME EDITING DOES NOT AFFECT PLURIPOTENT
STEM CELL CHARACTERISTICS. To investigatewhether the genetic engineering and transgene
overexpression would affect stemness, we tested the
pluripotency of our cells after ZFN editing and
transgene overexpression and observed that all the
transgenic cell lines displayed normal morphology
relative to control unmodiﬁed iPSCs (Online Fig. S4).
Additional testing revealed that transgenic cells
maintained their pluripotent state, as indicated by
the expression of pluripotency markers, such as Oct4,
Tra-1–60, Sox2, Tra-1–81, Nanog, and SSEA4 (Fig. 1C,
Online Fig. S5). Functionally, these cells were capable
of differentiation into all three germ layers both
in vitro (Fig. 1D, Online Fig. S6A) and in vivo (Fig. 1E,
Online Fig. S6B). The transgenic cells exhibited
normal karyotypes (Online Fig. S7). Taken together,
these results show that transgenic iPSCs maintained
their pluripotent potential after genetic engineering
and transgene overexpression.
ZFN EDITING AND TRANSGENE EXPRESSION DOES
NOT INFLUENCE WHOLE GENOME EXPRESSION
PROFILE. We next differentiated the transgenic
iPSCs into cardiomyocytes (iPSC-CMs) in vitro
through the use of a modiﬁed monolayer protocol, as
previously described (19). After 12 days of differen-
tiation, cell beating was observed for both unedited
(Online Video 1) and transgenic (Online Video 2 for
ziR190Q, Online Video 3 for ziG269S, Online Video 4
for ziG345E, and Online Video 5 for ziA614V) iPSC-
CMs. The cardiac marker expression (a-actinin,
TNNT2, MLC2a, and MLC2v) in the transgenic iPSCs
was similar to those seen in control unedited iPSCs
(Fig. 2A). To study whether the genetic engineering
and ion channel gene overexpression inﬂuence the
expression of other genes in iPSC-CMs, gene ex-
pression array (Affymetrix, Santa Clara, California)
was performed with genome-edited ziG269S iPSC-
CMs, patient-derived G269S iPSC-CMs (piG269S) (3),
and unedited iPSC-CMs. As shown in Figure 2B, 20
genes that were closely related to the action poten-
tial forming, calcium handling, and conductivity of
the iPSC-CMs were compared among the three
groups. As expected, the KCNQ1 gene is upregulated
in the ziG269S group, yet no obvious changes were
shown in the expression level of other genes. Over-
all, our microarray analysis showed very similar
gene expression patterns in these 3 groups, and
the correlation between any 2 groups are no less
than 97.5% (Figs. 2C and 2D). In addition, we also
tested the expression of a panel of ion channel gene
expression by quantitative PCR, and their expression
was similar to that for the unedited iPSC-CMs,
except the transgenes were overexpressed (Online
Fig. S8).
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FIGURE 2 Transgene Overexpression Did Not Change the Whole Genome Gene Expression Proﬁle
(A) The zinc ﬁnger nuclease (ZFN)-edited induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) expressed normal cardiac markers that included TNNT2
(top, red), actinin (top, green), MLC2a (bottom, red), and MLC2v (bottom, green) (also see Online Videos 1, 2, 3, 4, and 5). (B) Microarray analysis of gene expression
pattern for unedited, patient-speciﬁc piG269S, and ZFN-edited ziG269S iPSC-CMs. The expression proﬁles of 20 key genes in action potential formation and calcium
handling were plotted as a heat map. Note that KCNQ1 was overexpressed in ziG269S iPSC-CMs. (C) Pearson’s correlation analysis of expression proﬁle from 3 lines of the
tested iPSC-CMs. (D) Scatterplot comparison of the whole-genome wide gene expression pattern of the unedited, piG269S, and ziG269S iPSC-CMs.
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455TRANSGENIC iPSC LINES RECAPITULATED LQTS
PHENOTYPES. To assess whether the genome-edited
iPSC-CMs recapitulated the LQTS phenotype, patch-
clamp recordings were performed from single cells,
and cardiac action potentials were obtained. We ﬁrst
recorded the action potentials in parallel through
the use of iPSC-CMs derived from unedited iPSC,
ziG269S, and piG269S lines. Consistent with previous
reports, cardiac action potentials were recorded from
single iPSC-CMs, and all three subtypes of myo-
cytes (e.g., ventricular-like, atrial-like, and nodal-like)were detected in the three groups (Figs. 3A and 3B).
Key parameters of action potentials were collected
and assessed (Online Table S1). There were no sig-
niﬁcant changes observed in key parameters except
action potential duration at 90% repolarization
(APD90). The ventricular-like and atrial-like myocytes
derived from ziG269S exhibited signiﬁcantly longer
APD compared with unedited iPSC-CMs, which are
similar to the data obtained from piG269S iPSC-CMs.
More interestingly, both the ZFN-edited ziG269S
iPSC-CMs and patient-speciﬁc piG269S iPSC-CMs
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FIGURE 3 Whole-Cell Patch-Clamp Recording of Genome-Edited LQTS iPSC-CMs
(A) Action potential recordings from unedited, piG269S, and ziG269S induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) showing ventricular-like,
atrial-like, and nodal-like morphologies. All the long QT syndrome (LQTS) iPSC-CMs displayed the marked action potential duration (APD) prolongation in both
ventricular-like and atrial-like iPSC-CMs. (B) APD50, APD70, and APD90 values in unedited control and LQTS iPSC-CMs. **p < 0.01 when compared with control cells.
Error bars show mean  SEM. (C) Development of triggered activity in LQTS iPSC-CMs, manifested as early afterdepolarizations or even single and multiple triggered
beats. The early afterdepolarizations or aberrant beats are indicated by black arrows.
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456displayed early afterdepolarizations, which were not
present in unedited iPSC-CMs (Fig. 3C). In addition, we
also recorded action potentials from ziR190Q, ziG345E,
ziA614V, and patient-derived A614V (piA614V) iPSC-
CMs (10), all of which showed signiﬁcantly prolonged
APDs compared with the unedited iPSC-CMs (Online
Fig. S9, Online Table S1), consistent with previous
studies (10,11). In conclusion, ZFN-edited LQTS iPSC
lines can faithfully recapitulate the disease pheno-
type, which is similar to the one obtained from the
patient-speciﬁc, mutation-matched iPSC lines.
GENOME-EDITED iPSC-CMs AS A NEW PLATFORM
FOR DRUG TESTING. To evaluate the suitability of the
ZFN-edited iPSC disease model as a tool for drug
screening, we next tested nifedipine (a speciﬁc Ca2þ
blocker) on both ziG269S and piG269S iPSC-CMs.
Consistent with previous studies (10), when tested on
piG269S iPSC-CMswith a long APD baseline, nifedipine
(100 nmol/l) can shorten the APD as the result of its
Ca2þ blockade effect (Figs. 4A and 4B). Interestingly,
nifedipine also can signiﬁcantly shorten the APDwhen
tested in ziG269S iPSC-CMs (Figs. 4A and 4B),indicating that the genome-edited iPSC-CMs can be
used as a new platform for drug testing. To conﬁrm the
conclusion above, we recorded spontaneous calcium
transient in iPSC-CMs (Online Table S2). Compared
with unedited control iPSC-CMs, both ziG269S and
piG269S iPSC-CMs exhibited greater prolongation of
transient duration 90 by 63.6  7.9% and 60.8  8.6%,
respectively (Online Table S2). After treatment with
nifedipine, the transient duration 90 in both ziG269S
and piG269S iPSC-CMs was signiﬁcantly shortened,
similar to the results obtained from patch clamping
recording. We further tested the effect of pinacidil, a
KATP channel opener that can augment outward po-
tassium currents. Interestingly, pinacidil (100 nmol/l)
also can shorten the transient duration 90 of both
ziG269S and piG269S iPSC-CMs (Online Fig. S10,
Online Table S2). Taken together, these data suggest
that both genome-edited iPSC models and patient-
derived iPSC models can be used for drug screening,
with the added advantage that the former approach
obviates patient recruitment, which can be time-
consuming and unpredictable (Central Illustration).
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FIGURE 4 Drug Evaluation With the Use of Genome-Edited LQTS iPSC-CMs
(A) Action potential duration (APD) shortening was induced by 100 nmol/L nifedipine in long QT syndrome (LQTS) induced pluripotent stem
cell cardiomyocytes (iPSC-CMs). The left panel shows that nifedipine shortens patient-speciﬁc piG269S iPSC-CMs. The right panel shows
nifedipine shortens zinc ﬁnger nuclease (ZFN)-edited ziG269 iPSC-CMs. (B) APD90 before and after nifedipine treatment was quantiﬁed.
**p < 0.01 versus baseline by Student’s t-test.
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457DISCUSSION
In the present work, we demonstrated a new strategy
to create human PSC-based disease modeling by
overexpression of genes with dominant negative mu-
tations. This strategy is easy and highly efﬁcient. With
the use of this strategy, we successfully generated six
cell lines representing LQTS1 and LQTS2 in a short
period of time. Importantly, the unedited parent cell
lines can serve as an isogenic control. We further
showed that this strategy can be used as an effective
platform for drug screening (Central Illustration).
Human PSCs represent an excellent system for
disease modeling because they can be potentially
differentiated to any cell types present in the human
body. However, obtaining human PSCs with speciﬁc
disease-causing genetic mutations can be unpredict-
able and time-consuming. By contrast, genetic engi-
neering strategy to generate iPSC-based disease
models is much easier and faster. The reagents and
methods to engineer the AAVS1 locus already exist
and have been optimized (16,18). An investigator withbasic molecular biology skills can generate appro-
priate cell lines in three steps: identifying a gene with
desired dominant negative mutations, cloning the
gene into the targeting vector, and integrate the
construct into the AAVS1 locus, following the pro-
vided protocol. One person can generate several dis-
ease models in 3 months with the use of this strategy.
The quality of the studies depends on the avail-
ability of appropriate controls, and hence, any phe-
notypes observed in the PSC-derived cells should only
be interpreted through comparison with control cells,
which ideally would have the same genetic back-
ground as themutant PSCs andwould differ only in the
disease-linked gene. The usual practice is to generate
control iPSC lines from a close relative of the patient
who is age-matched and unaffected by the disease
within the same pedigree, but they are often unavai-
lable and represent only an approximate control.
Differences in genetic background are another
major concern. Even in studies in which healthy sib-
lings have been used as controls for disease patients,
only w50% of the genome is shared between any
CENTRAL ILLUSTRATION Generation of Isogenic Human Induced Pluripotent Stem Cell Lines for Cardiac Disease Modeling and
Drug Testing
A rapid and efﬁcient strategy was developed to generate human pluripotent stem cell–based disease models with isogenic control. First, ion
channel genes, KCNQ1 or KCNH2, with dominant negative mutations causing long QT syndrome (LQTS), were introduced into human embryonic
stem cells (ESCs) or induced pluripotent stem cells (iPSCs). To achieve stable transgene expression, the ion channel genes were integrated into
AAVS1 locus through the use of zinc ﬁnger nuclease (ZFN) technology. The speciﬁcity of the addition process was validated by genomic
polymerase chain reaction and Southern blot; the transgene expression was validated by immunostaining; the pluripotency of the transgenic
cells was conﬁrmed by in vivo teratoma analysis and in vitro embryoid body differentiation. Next, the transgenic cells were differentiated into
cardiomyocytes (CMs), with the unedited cells serving as an isogenic control. The CMs were conﬁrmed by immunostaining of the marker gene
expression. Gene expression array analysis revealed that the transgene expression did not inﬂuence the whole-genome gene expression proﬁle.
The electrophysiology analysis showed that the ZFN-edited iPSC-CMs displayed prolonged action potential duration (APD), a typical
phenotype of the LQTS-CMs. Finally, the application of ZFN-edited iPSC-CMs for drug screening was investigated. The addition of nifedipine
(L-type calcium channel blocker) or pinacidil (KATP-channel opener) shortened the APD of iPSC-CMs, conﬁrming the validity of isogenic iPSC
lines for drug testing in the future.
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458siblings. Furthermore, phenotypic differences could
be the result of DNA variants in the otherw50% of the
genome rather than the disease-associated mutations
(20). By contrast, the strategy we developed in this
study can use un-modiﬁed parental cell line as an
isogenic control, which genetically differs from the
transgenic cell lines only in the introduced gene.
In our study, the ion channel genes with dominant
negative mutations were overexpressed in the trans-
genic cells. The iPSC-CMs derived from transgenic
PSCs showed normal cardiac gene expression, with-
out changing the whole genome gene expression
proﬁle of the resultant cells. These iPSC-CMs reca-
pitulated LQTS phenotypes and had prolonged APD.
Importantly, the iPSC-CMs derived from both patient-
speciﬁc and genome-edited iPSCs showed similar
response to drugs that affect ion channels, demon-
strating that transgenic iPSCs can be used for drug
screening in the future.
It is widely recognized that human PSC-CMs are
immature. Previous studies have shown that human
ESC-CMs expressed cardiac genes at levels similar to
those found in 20-week fetal heart cells (21,22).
Mummery et al. (23) have shown that the upstroke
velocities for the ventricular-like cells were low but
comparable to those in cultured human fetal ven-
tricular cardiomyocytes. Nevertheless, several publi-
cations have revealed that these cells are capable of
capturing speciﬁc traits of an electrical disease of theheart, including LQTS1 (3,11), LQTS2 (10), LQTS3 (24),
and LQTS8 (6,25).
Finally, disease-speciﬁc iPSCs have enormous po-
tential for drug screening (26). Proof of principle for
iPSC models as a platform for small-molecule and
chemical testing already exists. For example, neurons
from spinal muscular atrophy (27) and familial dys-
autonomia (28) displayed in vitro defects that could
be corrected by candidate drugs, and the effect of
b-blocking drugs has been evaluated for LQTS iPSC-
CMs (11). However, the possibility that the geneti-
cally edited PSCs could be used as a platform for the
drug screening was not investigated until now.
In this study, we demonstrate that the LQTS
phenotype of the genome edited iPSCs-CMs can
be corrected by the nifedipine and pinacidil. We
further showed that the genetically edited LQTS
models worked equally well on the patient LQTS
iPSC models. In summary, our study provides in-
vestigators a robust and reliable system to generate
isogenic iPSC lines, which will be useful for disease
modeling, drug discovery, and regenerative medicine
in the future (26).
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PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: Intro-
ducing ion channel genes with dominant negative muta-
tions causing long QT syndrome into human induced
pluripotent stem cells can generate cardiomyocytes
that display the long QT phenotype, including
prolonged action potential duration.
TRANSLATIONAL OUTLOOK 1: The integration of
transgenes into speciﬁc loci through the use of zinc
ﬁnger nuclease technology avoids random mutagenic
integration and epigenetic silencing through viral
insertions and may be applicable to modeling of
other diseases caused by dominant negative
mutations.
TRANSLATIONAL OUTLOOK 2: This strategy has the
potential to accelerate modeling of genetic diseases for
identiﬁcation of novel drug targets and testing pharma-
cological strategies in vitro to improve the likelihood of
clinical efﬁcacy.
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